COMING IN OCTOBER FROM
The Outcomes Creativity Index (OCI) is a ranking of pharmaceutical companies and brands according to creativity and innovation.
The OCI is an aggregate score-based creative achievement representing these U.S. and International award shows: The Outcomes LLC/ Med Ad News Manny Awards, Cannes Lions, LIA: Health and Wellness, Clio Health, The One Show: 58 Health, Wellness & Pharma, The MM&M Awards, OUTCOMES CREATIVITY INDEX The Global Awards, and The Creative Floor Awards. Every year, Med Ad News recognizes the MANNY AWARDS — 7 CANNES LIONS — 15 top ten pharma companies and top ten brands LIA: HEALTH & WELLNESS — 7 according to their ranking in the October edition CLIO HEALTH — 7 of Med Ad News, which includes a Q&A with the THE ONE SHOW: HW&P — 7 number one company’s CMO and number one THE MM&M AWARDS — 4 brand’s marketing team. THE GLOBAL AWARDS — 7 THE CREATIVE FLOOR AWARDS — 4
top 50 pharma companies
Johnson & Johnson One Johnson & Johnson Plaza, ew runswick, J 0 9 58 OUTCOMES CREATIVITY INDEX Telephone: 2- 2 -0 00 Website: n .com MANNY AWARDS — 7 CANNES LION — 15 LIA: HEALTH & WELLNESS — 7 CLIO HEALTH — 7 THE ONE SHOW: HW&P — 7 THE MM&M AWARDS — 4 THE GLOBAL AWARDS — 7 De ning the THE CREATIVE FLOOR AWARDS — 4
future of healthcare BEST SELLING RX PRODUCTS 2017 2016 PRODUCT SALES SALES The e ecutive management team of this 1 2-year-old Remicade , 1 ,9 startup company is e cited about a future that lies beyond Stelara ,011 ,2 2 Invega Sustenna/ 2, 9 2,21 the intersection of science and technology. eplion, Invega Trinza/ Time Period: Invega Trevicta ytiga 2, 0 2,2 0 hroughout the de- phrenia), Oncology (e.g., prostate arelto 2, 00 2,2 cades, Johnson & cancer and hematologic malig- Imbruvica 1, 9 1,2 1 Johnson has ad- nancies), Cardiovascular and Simponi, 1, 1, August 2019 Creative Floor Awards T Simponi Aria vanced with the evo- Metabolism (e.g., thrombosis and Prezista, 1, 21 1, 1 lution of science and technology diabetes) and Pulmonary Hyper- Prezcobi /Rezolsta, – whether via the company’s pi- tension (e.g., Pulmonary Arterial Symtuza oneering development of sterile Hypertension). The latter is a arzale 1,2 2 2 to June 2020 Manny Awards surgery at the turn of the 20th new therapeutic area that was es- elcade 1,11 1,22 Invokana, 1,111 1, 0 century – or today as 134,000 tablished with the acquisition of Invokamet employees work together to Actelion in June 2017. The Med- Procrit/Epre 9 2 1,10 develop a diff erentiated robot- ical Devices segment consists of a Risperdal Consta 0 9 ic-assisted surgery platform in broad range of products used in “Our strong second-quarter (2018) results reflect double- Concerta/ 91 orthopaedics, build novel regi- the orthopaedic, surgery, cardio- methylphenidate digit growth in our Pharmaceutical business and the Edurant/rilpivirine 1 mens to boost T cells and train vascular, diabetes care and eye accelerating sales momentum in our Medical Devices Opsumit them to recognize and attack health fi elds. The Consumer seg- business, driven by the continued growth of our market All sales are in millions of dollars. Results: cancer through groundbreaking ment encompasses a wide array immuno-oncology eff orts, and of products used in the baby care, leading products and strategic new launches. We remain focused on investing in innovation and meeting the needs FINANCIAL PERFORMANCE focus to create the fi rst vaccine oral care, beauty, over-the-count- 2017 2016 for HIV/AIDS. Management er pharmaceutical, women’s of our customers by delivering innovative products and Revenue , 0 1, 90 says these are just some of the health and wound-care markets. solutions that position the company to deliver long-term, et income 1, 00 1 , 0 The scoring system is based on many examples that underscore “Our Pharmaceutical business sustainable growth. Our talented J&J colleagues are united iluted EPS 0. .9 J&J’s commitment to lead the has delivered outstanding and in our efforts to address some of the most critical health and R&